Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream [Letter]
Alessandro Mazzetti,1 Kizito Kyeremateng,2 Luigi Moro1 1Cassiopea S.p.A., Lainate, Italy; 2Sun Pharmaceutical Industries, Inc., Princeton, NJ, USACorrespondence: Kizito Kyeremateng, Sun Pharmaceutical Industries, Inc, 2 Independence Way, 2nd Floor, Princeton, NJ, 08540, USA, Tel +1 640-230-0831, Ema...
Saved in:
Main Authors: | Mazzetti A (Author), Kyeremateng K (Author), Moro L (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
by: Sanchez C, et al.
Published: (2022) -
Comparison of the Efficacy of Clascoterone, Trifarotene, and Tazarotene for the Treatment of Acne: A Systematic Literature Review and Meta-Analysis
by: Mahek Shergill, et al.
Published: (2024) -
The cutaneous effects of androgens and androgen-mediated sebum production and their pathophysiologic and therapeutic importance in acne vulgaris
by: James Q. Del Rosso, et al.
Published: (2024) -
Use of topical clascoterone for the treatment of hidradenitis suppurativa
by: Kaitlynne N. Cunningham, BS, et al.
Published: (2023) -
Safety and efficacy of tazarotene foam for the treatment of acne vulgaris
by: Epstein E, et al.
Published: (2013)